Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of claims:

1. (Currently amended) A pharmaceutical formulation ~~comprising~~consisting of a pharmaceutical acceptable salt of glycopyrronium~~, a solvate or physiologically functional derivative thereof~~ in combination with ciclesonide, ~~a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof~~ and lactose monohydrate~~a pharmaceutically acceptable carrier and/or one or more excipients~~,

wherein the pharmaceutical acceptable salt of glycopyrronium is the enantiomerically enriched R,R-form, (3R,2'R)-3-[(cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium,

wherein the enantiomerically enriched R,R-form has an enantiomeric purity of 90% minimum enantiomeric excess (ee), and

wherein the pharmaceutical formulation is a fixed combination as a dry powder.

2. (Canceled).

3. (Canceled).

4. (Currently amended) The formulation according to claim 1, ~~comprising a compound~~wherein the ciclesonide is selected from the group consisting of [11β,16α-(R)]-16,17-[(Cyclohexylmethylen)bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy)pregn

a-1,4-dien-3,20-dion, [11β,16α(S)]-16,17-[(Cyclohexylmethylen)bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxoprop-oxy)pregna-1,4-dien3,20-dion, [11β,16α(R,S)]-16,17-[(Cyclohexylmethylen)bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxoprop-oxy)pregna-1,4-dien3,20-dion, 16α,17- (22R)-Cyclohexylmethylendioxy-11β,21-dihydroxypregna-1,4-dien-3,20-dion, 16α,17-(22S)- Cyclohexylmethylendioxy-11β,21-dihydroxypregna-1,4-dien-3,20-dion and 16α,17- (22R,S)-Cyclohexylmethylendioxy-11β,21-dihydroxy-pregna-1,4-dien-3,20-dion.

5. (Canceled).

6. (Canceled).

7. (Canceled).

8. (Previously presented) The formulation according to claim 1, wherein the pharmaceutical acceptable salt of glycopyrronium is (3R,2'R)-3-[(cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium bromide, which substantially does not contain glycopyrronium in the S,S-, S,R- and/or R,S- forms.

9. (Currently amended) The formulation according to claim 1, ~~comprising~~wherein the pharmaceutical acceptable salt of glycopyrronium and ciclesonide are present in an amount and ratio to be effective for a twice or once daily treatment of a clinical condition in a mammal for which a corticosteroid and/or an anticholinergic agent is indicated.

10. (Previously presented) The formulation according to claim 1, which is suitable for administration by inhalation.

11. (Previously presented) The formulation according to claim 1, which is suitable for nasal administration.

12. (Canceled).

13. (Canceled).

14. (Withdrawn) A method of treatment of a clinical condition in a mammal, for which a corticosteroid and/or an anticholinergic agent is indicated, which comprises administration of a therapeutically effective amount of a pharmaceutical formulation comprising ciclesonide or a pharmaceutical acceptable salt, solvate, or physiologically functional derivative thereof in combination with a pharmaceutical acceptable salt of glycopyrronium, a solvate, or physiologically functional derivative thereof, and a pharmaceutical acceptable carrier and/or one or more excipients.

15. (Withdrawn) The method according to claim 14, wherein the clinical condition is selected from the group consisting of asthma, nocturnal asthma, exercise-induced asthma, chronic obstructive pulmonary diseases (COPD), chronic bronchitis, wheezy

bronchitis, emphysema, shortness of breath, respiratory tract infection, upper respiratory tract disease, rhinitis, allergic rhinitis and seasonal rhinitis.

16. (Withdrawn) The method according to claim 15, which comprises a twice daily dosage regimen.

17. (Withdrawn) The method according to claim 15, which comprises a once daily dosage regimen.

18. (Withdrawn) The method according to claim 15, which comprises administration of a combination of a pharmaceutical acceptable salt of glycopyrronium and ciclesonide in the same administration form by inhalation from an inhaler and wherein each actuation provides a dose therapeutically effective for a twice daily dosing regiment or for a once daily dosing regiment.

19. (Currently amended) A dry powder inhalation product comprising a pharmaceutical composition according to claim 1[[13]].